REDHILL ​​BIOPHAR / S (RDHL) receives Buy Rating from HC Wainwright



REDHILL ​​BIOPHAR / S (NASDAQ: RDHL)The shares of the shares were reassessed by the research analysts of shares at HC Wainwright in a research report that was issued on Tuesday 31 July.

The analysts wrote: "We maintain our Buy rating on RedHill and our twelve-month price target of $ 36.00 per ADS based on the average of two valuation methods: (1) price-sales multiple with a sales estimate of 7x 2025 discounted at 14%; and (2) analysis of multiple profit margins, where a 15x multiple is applied to our estimated income of 2025, also discounted at 14% (1) commercial, (2) regulatory, (3) clinical, (4) partnership, (5 ) financially and (6) intellectual property. ""

A number of other equity analysts have also issued reports about the company. Zacks Investment Research released REDHILL ​​BIOPHAR / S with a & # 39; hold & # 39; credit to a & # 39; buy & # 39; credit rating and set a target of $ 6.75 on the shares in a report on Saturday, May 12. ValuEngine reduced REDHILL ​​BIOPHAR / S from a & # 39; hold & # 39; credit to a & # 39; sell & # 39; rating in a report on Monday, July 30. Finally, LADENBURG THALM / SH SH started to report on REDHILL ​​BIOPHAR / S in a report on Monday 25 June. They set a "buy" rating and a target price of $ 20.00 on the shares. Two equity research analysts assessed the shares with a sales score and six awarded a buy-rating to the company's shares. REDHILL ​​BIOPHAR / S currently has an average rating of "Buy" and a consensus target price of $ 19.96.

NASDAQ RDHL shares traded $ 0.17 during mid-day trading and reached $ 7.32. 85,900 shares of the company were traded compared to the average volume of 160,141. REDHILL ​​BIOPHAR / S has a 1-year low of $ 4.30 and a 1-year high of $ 11.49. The company has a market capitalization of $ 143.80 million, a P / E ratio of -2.73 and a beta of 0.75.

A hedge fund has recently increased its stake in REDHILL ​​BIOPHAR / S shares. ARK Investment Management LLC strengthened its position in REDHILL ​​BIOPHAR / S (NASDAQ: RDHL) by 8.6% in the second quarter, according to the company in its most recent Form 13F application to the Securities & Exchange Commission. The company owned 112,648 shares of the biotechnology company's shares after purchasing an additional 8,894 shares during the period. ARK Investment Management LLC owned approximately 0.53% REDHILL ​​BIOPHAR / S worth $ 961,000 from the most recent filings with the Securities & Exchange Commission. 20.46% of the shares are currently held by institutional investors and hedge funds.

About REDHILL ​​BIOPHAR / S

RedHill Biopharma Ltd., a specialized biopharmaceutical company, focuses on the development and commercialization of drugs for the late clinical phase for the treatment of gastrointestinal disorders. It commercialises and promotes gastrointestinal products in the United States. The company's pipeline includes several drug candidates that are in advanced clinical development stages, including three phase III phase programs.

See also: what do investors mean by earnings per share?

Recommendations for analysts for REDHILL ​​BIOPHAR / S (NASDAQ: RDHL)

Receive daily news and ratings for REDHILL ​​BIOPHAR / S – Please provide your email address below for a concise, daily summary of the latest news and reviews from analysts for REDHILL ​​BIOPHAR / S and related companies with the FREE daily email newsletter from MarketBeat.com.


Source link

REDHILL ​​BIOPHAR / S (RDHL) receives Buy Rating from HC Wainwright



REDHILL ​​BIOPHAR / S (NASDAQ: RDHL)The shares of the shares were reassessed by the research analysts of shares at HC Wainwright in a research report that was issued on Tuesday 31 July.

The analysts wrote: "We maintain our Buy rating on RedHill and our twelve-month price target of $ 36.00 per ADS based on the average of two valuation methods: (1) price-sales multiple with a sales estimate of 7x 2025 discounted at 14%; and (2) analysis of multiple profit margins, where a 15x multiple is applied to our estimated income of 2025, also discounted at 14% (1) commercial, (2) regulatory, (3) clinical, (4) partnership, (5 ) financially and (6) intellectual property. ""

A number of other equity analysts have also issued reports about the company. Zacks Investment Research released REDHILL ​​BIOPHAR / S with a & # 39; hold & # 39; credit to a & # 39; buy & # 39; credit rating and set a target of $ 6.75 on the shares in a report on Saturday, May 12. ValuEngine reduced REDHILL ​​BIOPHAR / S from a & # 39; hold & # 39; credit to a & # 39; sell & # 39; rating in a report on Monday, July 30. Finally, LADENBURG THALM / SH SH started to report on REDHILL ​​BIOPHAR / S in a report on Monday 25 June. They set a "buy" rating and a target price of $ 20.00 on the shares. Two equity research analysts assessed the shares with a sales score and six awarded a buy-rating to the company's shares. REDHILL ​​BIOPHAR / S currently has an average rating of "Buy" and a consensus target price of $ 19.96.

NASDAQ RDHL shares traded $ 0.17 during mid-day trading and reached $ 7.32. 85,900 shares of the company were traded compared to the average volume of 160,141. REDHILL ​​BIOPHAR / S has a 1-year low of $ 4.30 and a 1-year high of $ 11.49. The company has a market capitalization of $ 143.80 million, a P / E ratio of -2.73 and a beta of 0.75.

A hedge fund has recently increased its stake in REDHILL ​​BIOPHAR / S shares. ARK Investment Management LLC strengthened its position in REDHILL ​​BIOPHAR / S (NASDAQ: RDHL) by 8.6% in the second quarter, according to the company in its most recent Form 13F application to the Securities & Exchange Commission. The company owned 112,648 shares of the biotechnology company's shares after purchasing an additional 8,894 shares during the period. ARK Investment Management LLC owned approximately 0.53% REDHILL ​​BIOPHAR / S worth $ 961,000 from the most recent filings with the Securities & Exchange Commission. 20.46% of the shares are currently held by institutional investors and hedge funds.

About REDHILL ​​BIOPHAR / S

RedHill Biopharma Ltd., a specialized biopharmaceutical company, focuses on the development and commercialization of drugs for the late clinical phase for the treatment of gastrointestinal disorders. It commercialises and promotes gastrointestinal products in the United States. The company's pipeline includes several drug candidates that are in advanced clinical development stages, including three phase III phase programs.

See also: what do investors mean by earnings per share?

Recommendations for analysts for REDHILL ​​BIOPHAR / S (NASDAQ: RDHL)

Receive daily news and ratings for REDHILL ​​BIOPHAR / S – Please provide your email address below for a concise, daily summary of the latest news and reviews from analysts for REDHILL ​​BIOPHAR / S and related companies with the FREE daily email newsletter from MarketBeat.com.


Source link

Leave a Reply